EGFR and lung carcinoma: In summary, our study demonstrated that the LXR agonist T0901317 sensitizes EGFR‐TKI‐resistant human lung cancer cell A549 to EGFR‐TKI treatment in vitro, and this effect was partly achieved by inhibition of the PI3K/Akt signaling pathway.